Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Growth Factors Identified for Current Orphan Drug Market

By BiotechDaily International staff writers
Posted on 08 Jul 2013
A new market research report by Kalorama Information (Rockville, MD, USA) identifies factors likely to have stimulated the current orphan drug market, with further growth expected for the next forecast period.

Drugs for treating rare conditions are commonly referred to as "orphan drugs." The global orphan drug market reached 61 billion in 2012, according to Kalorama. The new Kalorama report - "The World Market for Orphan Drugs" - states that the increasing incidence of diseases affecting the aged will drive the market to increase at a rate of 11.5% throughout the forecast period, reaching USD 105.2 billion by 2017. In the USA, the largest market, Congress determined that adequate therapies for many rare diseases had not been developed because companies could not expect an orphan drug to make sufficient profit; therefore, incentives were needed for developing such drugs. According to Kalorama, these incentives have worked, helping to create a thriving market for this sector of treatments.

The report breaks out the market by company and by category. Non-Hodgkin's lymphoma, multiple myeloma, renal disease, and osteoporosis are among the diseases where treatments are not sufficient, according to the report. "In these markets regulators have allowed new orphan therapies," said Bruce Carlson, publisher, Kalorama Information, "Pharmaceutical companies have seen an opportunity in developing drugs with reduced regulatory costs and incentivized development."

Kalorama's estimate relates to the market where only orphan drug-designation revenue is included. Other estimates may also include brand revenue not truly occurring from an orphan designation. A product available as an orphan drug in one country may be available under traditional marketing approval in another. Some products that gain orphan status are later granted approval and removed from the orphan drug database at the developer's request. Factors involved in also include reimbursement, regulation, disease status, and general development, all of which were taken into account in Kalorama's study.

The report also presents major and small pharmaceutical companies' activities within this drug category, their market share, and predicts leading market contributers.

Related Links:
Kalorama Information
Kalorama Orphan Drugs Report


WATERS CORPORATION

Channels

Genomics/Proteomics

view channel
Image: Exosomes loaded with catalase (shown in red) efficiently interact with neurons (shown in black) to protect them from the effects of Parkinson\'s disease (Photo courtesy of Dr. Elena Batrakova, University of North Carolina).

Exome Delivery of the Anti-Oxidant Catalase Reduces Parkinson's Disease Symptoms in Mouse Model

The exosome delivery of the antioxidant enzyme catalase was shown to dramatically reduce symptoms of Parkinson's disease (PD) in a mouse model. Exosomes are cell-derived vesicles that are present in... Read more

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Lab Technologies

view channel
Image: The gene assembly robot, the GeneTheatre (Photo courtesy of Analytik Jena AG).

Genomic Research Laboratories Await New Compact Liquid Handling System

A small footprint benchtop liquid handler that automates multiple gene assembly tasks and associated procedures such as PCR setup is now available for use by biotech and genomic research laboratories.... Read more
 

Events

27 May 2015 - 28 May 2015
02 Jun 2015 - 03 Jun 2015
15 Jun 2015 - 18 Jun 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.